Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases
With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs.
Vertex Pharmaceuticals Inc. (NASDAQVRTX) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call.”
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline.
